Japanese Healthtech Stock News

Asahi Kasei (TSE:3407) has drawn fresh attention after starting a Phase I clinical trial for AK1940, a peptide-based autoimmune drug candidate that management links to its medium-term pharmaceutical growth plans. See our latest analysis for Asahi Kasei. The AK1940 trial and recent bond shelf registration activity come as Asahi Kasei’s share price trades at ¥1,524.5, with a 1-year total shareholder return of 55.53% and 3-year total shareholder return of 75.92%. This suggests momentum has been...

Investors in Tokyo Electron Limited ( TSE:8035 ) had a good week, as its shares rose 3.5% to close at JP¥47,450...

AEON REIT Investment (TSE:3292) has scheduled a board meeting for April 30, 2026, to approve a planned leadership reshuffle at its asset manager, including the appointment of veteran executive Muneaki Yamamoto as director. See our latest analysis for AEON REIT Investment. At a share price of ¥125,400, AEON REIT Investment has seen a 1 day share price return close to flat. Its year to date share price return of a 9% decline contrasts with a 1 year total shareholder return of 3.52%, suggesting...

Toyota Motor has recently outlined plans to build three new vehicle assembly plants in Maharashtra, India, investing about ¥300.00 billion (US$1.90 billion) to lift capacity toward one million units by the 2030s and support exports to the Middle East and Africa, while also partnering with Isuzu to mass-produce a light-duty fuel-cell electric truck using Toyota’s third-generation fuel cell system from fiscal 2027. Together, these moves signal Toyota’s effort to deepen its manufacturing...

Otsuka Corporation ( TSE:4768 ) just released its first-quarter report and things are looking bullish. The company beat...

Last week, you might have seen that West Japan Railway Company ( TSE:9021 ) released its full-year result to the...

The annual results for Heiwa Real Estate Co., Ltd. ( TSE:8803 ) were released last week, making it a good time to...

Shareholders might have noticed that ZOZO, Inc. ( TSE:3092 ) filed its yearly result this time last week. The early...

SBI Holdings (TSE:8473) has put solid numbers on the board for FY 2026 so far, with third quarter revenue of ¥587.1 billion and basic EPS of ¥278.09, alongside trailing twelve month revenue of ¥1.9 trillion and EPS of ¥650.41 that reflect a very large 218.4% earnings increase over the past year and a net profit margin moving from 9.5% to 21.4%. The company has seen revenue lift from ¥337.4 billion in the third quarter of FY 2025 to ¥587.1 billion in the third quarter of FY 2026, while...

DMG Mori (TSE:6141) has entered its Q1 2026 reporting season with recent quarterly numbers that include Q4 2025 revenue of ¥173,645 million and basic EPS of ¥4.51, set against trailing twelve month EPS figures that range from ¥33.68 to ¥153.31 on revenue between ¥524,261 million and ¥550,498 million. The company has seen revenue move from ¥154,190 million in Q4 2024 to ¥173,645 million in Q4 2025, while quarterly EPS shifted from ¥37.77 to ¥4.51 over the same period. This sets up a results...

The investors in TOTO LTD. 's ( TSE:5332 ) will be rubbing their hands together with glee today, after the share price...

As you might know, Lasertec Corporation ( TSE:6920 ) last week released its latest quarterly, and things did not turn...

Nxera Pharma (TSE:4565) has opened Q1 2026 earnings season with Q4 2025 revenue of ¥7.8 billion and a basic EPS loss of ¥85.32, alongside net income excluding extraordinary items of a ¥7.7 billion loss. Over recent quarters, the company has reported revenue between ¥6.6 billion and ¥8.5 billion, while basic EPS has ranged from a loss of ¥8.45 to a loss of ¥85.32 as profitability pressure has persisted. For investors, the focus this quarter is on how that revenue base relates to margins and...

GNI Group Ltd. announced that its consolidated subsidiary, Gyre Pharmaceuticals, has enrolled the first patient in a Phase 2/3 trial of its self-developed pirfenidone capsules (Etuary®) for radiation-induced lung injury with or without immune checkpoint inhibitor-related pneumonitis, following Chinese regulatory approval in March 2025. This step advances pirfenidone into oncology supportive care, targeting a serious complication of thoracic cancer treatment where current therapeutic options...

In April 2026, Otsuka Holdings Co., Ltd. reported first-quarter 2026 results showing sales of ¥630,342 million and net income of ¥98,348 million, both higher than the same period a year earlier, with basic earnings per share from continuing operations rising to ¥186.31. This combination of higher sales, stronger net income, and improved earnings per share suggests the company converted top-line growth into more efficient profitability in the quarter. We’ll now examine how this stronger...

Mitsubishi Corporation has released its full-year results for the period ended March 31, 2026, reporting sales of ¥18.92 trillion and net income of ¥800.46 billion, both slightly higher sales but lower profit than the previous year. The earnings report also showed a reduction in basic earnings per share from continuing operations to ¥210.92, highlighting pressure on profitability despite revenue growth. We’ll now examine how this weaker earnings profile, alongside the planned sale of...

Nikon (TSE:7731) is drawing investor attention after the commercial launch of its APDIS MV5X Laser Radar system, which uses Aeva’s Eve sensor technology under a multi-year production agreement for automated inspection and metrology. See our latest analysis for Nikon. The APDIS MV5X announcement arrives as Nikon’s share price shows mixed short term momentum, with a 7 day share price return of 7.49% contrasting with a 30 day share price return decline of 8.40%. The 1 year total shareholder...

Chugai Pharmaceutical Co., Ltd. reported first-quarter 2026 results with sales of ¥291,577 million, revenue of ¥321,747 million, and net income of ¥115,418 million, all higher than a year earlier. The board also moved to introduce a trust-based stock compensation system, highlighting how governance and incentive design are evolving alongside the company’s earnings profile. We’ll now examine how this strong first-quarter earnings growth shapes Chugai Pharmaceutical’s investment narrative and...

With Nippon Express Holdings catching your eye, the key question is whether the current share price around ¥4,121 reflects fair value or if the market is mispricing the stock. Recent returns have been strong, with the share price showing 8.6% over the last week, 13.8% over the last month, 21.8% year to date and 66.3% over the last year, along with 70.0% over three years and 70.5% over five years. Recent company news helps frame these moves for you, including updates around business...

Last week, you might have seen that NS Solutions Corporation ( TSE:2327 ) released its annual result to the market. The...

As you might know, Japan Exchange Group, Inc. ( TSE:8697 ) recently reported its full-year numbers. Results were...

The most recent earnings report from Nomura Research Institute, Ltd. ( TSE:4307 ) was disappointing for shareholders...

What the revised guidance and TRICOR impairments mean for investors Rengo (TSE:3941) has cut its full year profit outlook, even as sales guidance stays unchanged, after weaker profitability in its European heavy duty corrugated packaging business and substantial TRICOR related impairments. The company now expects operating profit of ¥37,000 million, compared with an earlier outlook of ¥40,000 million. Profit attributable to owners of parent is now expected to be ¥21,000 million, instead of...

Shareholders didn't appear too concerned by Tokyo Steel Manufacturing Co., Ltd.'s ( TSE:5423 ) weak earnings. We did...